Related Experiment Video

Updated: Mar 25, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

41.0K

High serum pentosidine in branch atheromatous disease among small vessels occlusion

Toshiki Ikeda1,2, Keisuke Maruyama3, Nobuyuki Ito3,4

  • 1Department of Cerebrovascular Surgery and Stroke Center, International Medical Center, Saitama Medical University, Saitama, Japan - schwein0920@me.com.

Journal of Neurosurgical Sciences
|February 23, 2016
PubMed

Insights

High serum pentosidine levels are linked to cerebral branch atheromatous disease (BAD), a condition causing worse outcomes in acute ischemic stroke patients. This finding aids in distinguishing BAD from lacunar infarction.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Biochemistry

Background:

  • Cerebral branch atheromatous disease (BAD) is associated with poorer stroke progression and neurological decline compared to lacunar infarction.
  • Advanced glycation end products, such as pentosidine, are implicated in atherosclerosis and plaque progression.
  • The relationship between serum pentosidine and small vessel occlusion, particularly BAD, remains underexplored.

Purpose of the Study:

  • To investigate the association between serum pentosidine levels and cerebral branch atheromatous disease (BAD) in patients with acute ischemic stroke.
  • To determine if serum pentosidine can differentiate BAD from lacunar infarction.
  • To identify serum pentosidine as an independent risk factor for BAD.

Main Methods:

  • Serum pentosidine levels were measured in 56 acute ischemic stroke patients (21 BAD, 35 lacunar).
  • Univariate and multivariate logistic regression analyses were employed to assess risk factors, including pentosidine.
  • Sensitivity and specificity of pentosidine for discriminating BAD from lacunar infarction were calculated.

Main Results:

  • Serum pentosidine levels were significantly higher in the BAD group (0.081±0.081 µg/mL) compared to the lacunar group (0.046±0.043 µg/mL) (P<0.05).
  • High serum pentosidine was significantly related to BAD in univariate analysis (P=0.01).
  • Multivariate analysis identified high serum pentosidine as the sole independent risk factor for BAD (P=0.03), with 90% sensitivity and 44% specificity.

Conclusions:

  • Elevated serum pentosidine levels in the acute phase of stroke are associated with cerebral branch atheromatous disease (BAD).
  • High pentosidine levels correlate with a worse outcome in patients experiencing small vessel occlusion.
  • Serum pentosidine may serve as a valuable biomarker for identifying BAD and predicting stroke outcomes.
Abstract

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.7K
Evaluation of Capillary and Other Vessel Contribution to Macular Perfusion Density Measured with Optical Coherence Tomography Angiography07:18

Evaluation of Capillary and Other Vessel Contribution to Macular Perfusion Density Measured with Optical Coherence Tomography Angiography

Published on: February 18, 2022

2.2K

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
649
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
593
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
732
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
737